H.C. Wainwright Keeps a Buy Rating on Mirum Pharmaceuticals (MIRM)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Mirum Pharmaceuticals (MIRM – Research Report) today and set a price target of $51.00. The company's shares closed last Tuesday at $19.39. According to TipRanks.com, Arce is a 5-star analyst with an average return of 18.5% and a 41.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mirum Pharmaceuticals with a $46.50 average price target, implying a 144.7% upside from current levels. In a report issued on September 13, Guggenheim also maintained a Buy rating on the stock with a $37.00 price target. See today’s analyst top recommended stocks >> The company has a one-year high of $26.31 and a one-year low of $13.85. Currently, Mirum Pharmaceuticals has an average volume of 90.67K. Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MIRM in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA. Read More on MIRM: Alliance Global Partners Thinks Syros Pharmaceuticals’ Stock is Going to Recover Universal Display Stock: Similar to Late-’90s Qualcomm Microsoft Stock: Rising Free Cash Flows, Bullish Outlook Analyst Sees Novavax Covid Vaccine as Potentially Useful to Boost Other Vaccines Wedbush Remains a Buy on Clearside Biomedical (CLSD) The post H.C. Wainwright Keeps a Buy Rating on Mirum Pharmaceuticals (MIRM) appeared first on TipRanks Financial Blog.

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Mirum Pharmaceuticals (MIRM – Research Report) today and set a price target of $51.00. The company's shares closed last Tuesday at $19.39.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 18.5% and a 41.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mirum Pharmaceuticals with a $46.50 average price target, implying a 144.7% upside from current levels. In a report issued on September 13, Guggenheim also maintained a Buy rating on the stock with a $37.00 price target.

The company has a one-year high of $26.31 and a one-year low of $13.85. Currently, Mirum Pharmaceuticals has an average volume of 90.67K.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MIRM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.

Read More on MIRM:

  • Alliance Global Partners Thinks Syros Pharmaceuticals’ Stock is Going to Recover
  • Universal Display Stock: Similar to Late-’90s Qualcomm
  • Microsoft Stock: Rising Free Cash Flows, Bullish Outlook
  • Analyst Sees Novavax Covid Vaccine as Potentially Useful to Boost Other Vaccines
  • Wedbush Remains a Buy on Clearside Biomedical (CLSD)

The post H.C. Wainwright Keeps a Buy Rating on Mirum Pharmaceuticals (MIRM) appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

What's Your Reaction?

like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0

Next Article

Cummins Stock: Patience Required for Investors

Cummins Inc. (CMI), is an industrial giant with a strong competitive advantage. The company designs, manufactures, distributes, and services diesel and natural gas engines, electric and hybrid powertrains, and related Read More... The post Cummins Stock: Patience Required for Investors appeared first on TipRanks Financial Blog.

Cummins Stock: Patience Required for Investors

Cummins Inc. (CMI), is an industrial giant with a strong competitive advantage.

The company designs, manufactures, distributes, and services diesel and natural gas engines, electric and hybrid powertrains, and related components worldwide.

It operates through five segments: Engine, Distribution, Components, Power Systems, and New Power.

Cummins is trading at a low forward multiple, but we remain neutral in the short-term because we believe we may be able to get a better entry point. (See Cummins stock charts on TipRanks)

Measuring Its Competitive Advantage

We can measure Cummins’ competitive advantage by comparing its earnings power value to the value of reproducing the business. Earnings power value is measured as adjusted EBIT after tax, divided by the weighted average cost of capital, and reproduction value can be measured using total asset value. If earnings power value is higher than reproduction value, then a company is considered to have a competitive advantage.

Cummins’ average EBIT margin over the past five years was 10.4%. Using its revenue for the last 12 months, its adjusted EBIT is as follows:

$23.2 billion x 0.104 = $2.41 billion

Using a marginal tax rate of 22%, the after tax adjusted EBIT is $1.88 billion.

Cummins’ weighted average cost of capital is 6.8%. The earnings power value is $27.65 billion ($1.88 billion divided by 0.068).

Finally, its total asset value is $22.61 billion. As a result, Cummins has a competitive advantage because its earnings power value is greater than the reproduction value of the business.

Growth Catalysts, Risks

Cummins is currently trading at 15.3 times earnings and approximately 11.5 times forward earnings.

Since the company is cyclical, it’s more sensitive to business cycles. As a result, its P/E ratio tends to mostly hover between 10 to 20. However, Cummins does generate a lot of free cash flow which it regularly uses for dividends and buybacks.

The company’s share count continues to decrease every year as a result of the buybacks. This means that earnings per share will increase even if earnings stay flat. The increased EPS leads to a higher share price even if the P/E ratio stays in the same historical range.

In fact, Cummins’ EPS remained relatively flat from 2011 to 2016 despite seeing earnings decline over that same period. The stock mostly trended up during that time period nonetheless, although it did so with a lot of volatility. This demonstrates the impact that share buybacks can have.

Another growth catalyst for Cummins is its participation in developing new technology that uses green energy. In particular, the company is focusing on hydrogen energy. It’s already powering some trains in Europe with its fuel cells, in addition to other applications, ranging from grocery trucks to the first PEM electrolyzer in the United States.

However, like many manufacturers these days, Cummins is vulnerable to supply chain disruptions that lead to uncertainties about the company’s operations.

On top of that, increased costs of raw materials may impact the company’s margins if it’s not able to pass on the expense. In addition, there is always the cyclical risk that is associated with the industry.

Wall Street's Take

Turning to Wall Street, Cummins has a Moderate Buy consensus rating, based on four Buys and five Holds assigned in the past three months. The average Cummins price target of $278.67 implies 27.1% upside potential.

Final Thoughts

Cummins is undoubtedly an industry leader, with a measurable competitive advantage.

However, given the cyclical nature of the industry, a stock like Cummins produces the best returns after a cyclical sell-off. The stock has been on a downward trend for months now, and it’s possible that we are nearing a bottom.

Unless you can stomach a lot of volatility, it’s better to wait for momentum to pick up towards the upside before entering industrial stocks.

Disclosure: At the time of publication, Stock Bros Research did not have a position in any of the securities mentioned in this article.

​Disclaimer: The information contained in this article represents the views and opinion of the writer only, and not the views or opinion of TipRanks or its affiliates, and should be considered for informational purposes only. TipRanks makes no warranties about the completeness, accuracy or reliability of such information. Nothing in this article should be taken as a recommendation or solicitation to purchase or sell securities. Nothing in the article constitutes legal, professional, investment and/or financial advice and/or takes into account the specific needs and/or requirements of an individual, nor does any information in the article constitute a comprehensive or complete statement of the matters or subject discussed therein. TipRanks and its affiliates disclaim all liability or responsibility with respect to the content of the article, and any action taken upon the information in the article is at your own and sole risk. The link to this article does not constitute an endorsement or recommendation by TipRanks or its affiliates. Past performance is not indicative of future results, prices or performance.

The post Cummins Stock: Patience Required for Investors appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.